We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 593

FTC settles with health app marketers for unsubstantiated melanoma detection claims

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • February 25 2015

The Federal Trade Commission announced this week that it has reached settlements with two marketers for "deceptively claiming their mobile apps could

NAD recommends advertiser discontinue “1 Brand” and comparative strength claims

  • Winston & Strawn LLP
  • -
  • USA
  • -
  • February 25 2015

The National Advertising Division ("NAD") recently recommended that Splintek, Inc., a manufacturer of dental guards to protect against nighttime

First Amendment trumps FTC

  • Reed Smith LLP
  • -
  • USA
  • -
  • February 20 2015

The Federal Trade Commission has a long reach, but its grip is not quite as strong as it was before the D.C. Circuit's recent opinion in PomWonderful

Less is more in FDA’s eyes: FDA’s revised draft guidance on disclosing risk information

  • Hogan Lovells
  • -
  • USA
  • -
  • February 11 2015

On Monday, February 9, 2015, the Food and Drug Administration (FDA) published a revised draft guidance addressing disclosure of risk information

POM wonderful: implications for FTC and FDA substantiation requirements

  • Arnold & Porter LLP
  • -
  • USA
  • -
  • February 11 2015

On January 30, 2015 the D.C. Circuit issued a decision in POM Wonderful, LLC v. FTC, no. 13-1060, largely upholding an order by the Federal Trade

FDA rethinks consumer-directed print ads for drugs

  • Squire Patton Boggs
  • -
  • USA
  • -
  • February 10 2015

In 2004, the FDA promulgated requirements for drug print advertisements. FDA, 69 Fed. Reg. 6307 (May 10, 2004). Those regulations required "the

Update on recent case law restricting advertising of medicinal products

  • Baker & McKenzie
  • -
  • Germany
  • -
  • February 6 2015

Recent court decisions confirm the rigorous standard ("Strengeprinzip") applied by German courts when analyzing whether or not health claims in

D.C. Circuit upholds FTC ruling on deceptive advertising; rejects First Amendment challenge

  • Holland & Knight LLP
  • -
  • USA
  • -
  • February 6 2015

In a much-awaited decision on Friday, January 30, the D.C. Circuit upheld the Federal Trade Commission's decision that pomegranate juice maker POM

Court affirms FTC’s restriction on health and disease-related claims by Pom Wonderful

  • Klein Moynihan Turco LLP
  • -
  • USA
  • -
  • February 5 2015

The U.S. Court of Appeals for the District of Columbia Circuit recently affirmed a Federal Trade Commission ("FTC") decision that POM Wonderful, LLC

D.C. Circuit’s POM Wonderful decision points to reduced substantiation burden for advertisers

  • Debevoise & Plimpton LLP
  • -
  • USA
  • -
  • February 4 2015

On January 30, the D.C. Circuit Court of Appeals held in POM Wonderful, LLC, et al. V. Federal Trade Commission that the FTC did not have an adequate